secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-065633
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero posts Q4 net loss of $20.9M; revenue down 80% YoY; pipeline setbacks and SEC Wells Notice
--------------------------------------------------------------------------------

- Net loss of $20.9M in Q4 2024 vs net income of $51.2M in Q4 2023; diluted EPS loss of $(0.38).
- Total revenue fell to $15.0M from $73.5M YoY, driven by lower collaboration revenue from GSK and Pfizer.
- Tebipenem HBr Phase 3 PIVOT-PO interim analysis expected Q2 2025; SPR720 Phase 2a missed primary endpoint with three cases of grade 3 hepatotoxicity; SPR206 discontinued.
- Leadership change: Esther Rajavelu appointed Interim President and CEO in January 2025 following a Wells Notice from SEC related to disclosures in 2022.
- Cash of $52.9M as of Dec 31, 2024; plus GSK milestones provide runway into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/0001193125-25-065633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/d906623d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-065633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer